06.11.2007
Axxonis Pharma AG, Berlin, obtains financing with ETV Capital .
Axxonis Pharma AG, Berlin, today announces the closure of a financing deal.
Up to 10 million Euros of debt capital and additional private equity have been made available to the Axxonis Pharma AG. The private equity financed Axxonis Pharma AG has an advanced product pipeline with three late stage clinical development programs for the treatment of Parkinson’s Disease (“PD”) and Restless Legs Syndrome (“RLS”) based on continuous dopaminergic stimulation through its lead compound Lisuride.
For all three candidates regulatory submissions are under preparation. The European Drug Authority (EMEA) has recently accepted the Lisuride transdermal patch as well as subcutaneous Lisuride due to its significant therapeutic innovation for the centralized procedure.
The regulatory submission will be financed through the mezzanine capital. “These funds allow the Axxonis Pharma AG to finalize the EMEA application for marketing in the EU.” said Dr. Johannes Tack, CEO of Axxonis.
About Axxonis
Axxonis Pharma AG, Berlin, is a pharmaceutical company specialized on CNS products. Axxonis is developing a portfolio of internally discovered or licensed product candidates to improve the therapeutic benefits of existing drugs and develop
the products for indications of higher value. Axxonis’ most advanced product candidate, the Lisuride patch, is the subject of a Phase III clinical program for the treatment of RLS which has now been completed successfully. Axxonis has also reported positive results from a Phase III clinical trial of transdermal Lisuride (as separate brand) in patients with advanced Parkinson’s disease.
To learn more about Axxonis, please visit the website at www.axxonis.com.
About ETV Capital
ETV Capital is a specialty finance company that provides venture debt solutions to technology companies in Europe, the US and Israel. ETV operates 4 offices: London, Tel Aviv, Geneva and Frankfurt. For more details, please visit www.etvcapital.com.
Forward-Looking Statements
This press release contains "forward-looking" statements, including, without limitation, all statements related to our clinical development program with Lisuride and the timing thereof; the potential filing of a NDA with Lisuride; the therapeutic and commercial potential; potential milestone and royalty payments; and future commercialization plans. These forward-looking statements are based upon Axxonis' current expectations. Forward-looking statements involve risks and uncertainties. Axxonis' actual results and the timing of events could differ materially from those anticipated in such forwardlooking statements as a result of these risks and uncertainties, which include, without limitation, the ability of the company to successfully conduct the clinical trials, the uncertainty of the EMEA approval process and other regulatory requirements, the therapeutic and commercial value of the company's products and issues relating to regulatory approval, manufacturing and commercialization, Axxonis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements
are based.
Axxonis is a registered trademark.
back
